• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Thomas Frank E was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)

    6/25/26 6:59:52 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRO alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    THOMAS FRANK E

    (Last)(First)(Middle)
    C/O SPERO THERAPEUTICS, INC.
    675 MASSACHUSETTS AVENUE, 14TH FLOOR

    (Street)
    CAMBRIDGE MASSACHUSETTS 02139

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Spero Therapeutics, Inc. [ SPRO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/23/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock06/23/2026A10,000(1)A$0.0085,000D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (right to buy)$2.1506/23/2026A20,000 (2)06/23/2036Common Stock20,000$0.0020,000D
    Explanation of Responses:
    1. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
    2. The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
    /s/ Maegan Deare, Attorney-in-Fact for Frank E. Thomas06/25/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $SPRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPRO

    DatePrice TargetRatingAnalyst
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    9/23/2022$2.00 → $8.00In-line → Outperform
    Evercore ISI
    10/1/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SPRO
    SEC Filings

    View All

    Spero Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

    7/14/26 6:30:09 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Spero Therapeutics Inc.

    8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

    6/25/26 5:08:23 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Spero Therapeutics Inc.

    S-8 - Spero Therapeutics, Inc. (0001701108) (Filer)

    6/23/26 4:05:45 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

    Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt

    7/14/26 6:02:00 AM ET
    $SPRO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

    Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001)Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, totaling approximately US$1.1 billion, as well as tiered royalties on net salesSpero plans to initiate a Phase 2 trial for IBI355 in Q2 2027 in IgG4-related disease (IgG4-RD), a serious, chronic fibroinflammatory condition with significant treatment burden and limited therapeutic options Innovent plans to initiate a Phase 2 trial in China by early 2027 for Sjögren's disease (SjD), a

    7/14/26 6:00:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

    Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, totaling approximately US$1.1 billion, as well as tiered royalties on net salesSpero plans to initiate a Phase 2 trial for SP001 in Q2 2027 in IgG4-related disease (IgG4-RD), a serious, chronic fibroinflammatory condition with significant treatment burden and limited therapeutic options Innovent plans to initiate a Phase 2 trial in China by early 2027 for Sjögren’s disease (SjD), a chronic autoimmu

    7/14/26 6:00:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Deshpande Milind was granted 10,000 shares, increasing direct ownership by 11% to 101,454 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/25/26 7:26:49 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tregoning Kathleen was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/25/26 7:17:12 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Cynthia was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/25/26 7:14:32 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Spero Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Spero Therapeutics from Outperform to In-line and set a new price target of $5.00

    12/20/24 7:51:16 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Spero Therapeutics from In-line to Outperform and set a new price target of $8.00 from $2.00 previously

    9/23/22 7:52:34 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics downgraded by Oppenheimer

    Oppenheimer downgraded Spero Therapeutics from Outperform to Perform

    10/1/21 6:10:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Leadership Updates

    Live Leadership Updates

    View All

    Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

    LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. He is also Chairman of three privately held companies, Micreos Group (Bilthoven, Netherlands), Secura

    7/8/26 2:00:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

    WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per

    6/29/26 7:30:00 AM ET
    $KLRA
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways Elects Kathleen Tregoning to Board of Directors

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. "With two successful Phase 3 trials meeting the primary endpoint, a

    5/28/26 6:30:00 AM ET
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Financials

    Live finance-specific insights

    View All

    Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

    CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases w

    5/5/26 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

    CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di

    3/18/26 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

    CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug

    11/4/25 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

    SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    11/14/24 5:37:55 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Spero Therapeutics Inc.

    SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

    2/14/24 4:25:21 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

    SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    2/14/23 11:47:54 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care